Top Health Tech Companies in Bangalore (113)

Strong Revenue Growth: Consolidated revenues increased from $253 billion in 2024 to $270.6 billion in 2025, with quarterly gains such as Q4 2025 up 8% year over year. Growth was led primarily by Optum Rx and supported by steady contributions from Optum Insight.

Market Expansion: Expansion through acquisitions such as Holston Medical Group (August 2025) and Alegeus (July 2026), alongside earlier combinations like Change Healthcare and Atrius Health, broadened capabilities across care, pharmacy, and payments. These moves extend Optum’s platform into adjacent services and operating domains.

Diversified Revenue Streams: A multi-segment model—Rx, Insight, and Health—helps sustain aggregate growth even as individual lines vary, with pharmacy and technology businesses offsetting care-delivery softness. Parent-company commentary continuing to frame Optum as a growth engine and raising 2026 guidance underscores the benefit of this portfolio effect.

Strong Revenue Growth: Reported year-over-year software growth in 2024, alongside multi-year increases and net new client additions, indicates sustained commercial momentum. Customer penetration among large pharma is described as expanding across 2024–2025.

Investor Backing & Capital Strength: A majority investment by GI Partners, with Summit Partners remaining a minority investor, is described as supporting further scale, product investment, and global reach. This signals access to resources for continued expansion.

Strong Market Position & Advantage: Independent recognition as the highest-designated Leader in 2024 for life sciences clinical data and analytics platforms, coupled with adoption by numerous top biopharma companies, signals competitive strength in its core segment. Named client expansions further reinforce visibility and impact.

Market Expansion: Headcount and footprint are described as rising to more than 15,000 employees across 40-plus offices, alongside concrete new sites in Hyderabad and a completed Chicago buildout—signals of geographic and capacity expansion. These moves indicate confidence in demand across key delivery hubs.

Innovation-Driven Growth: A dedicated Platforms & Products unit, the ZAIDYN portfolio, and AI-agent initiatives point to sustained investment in productized, AI-enabled offerings. Capability-deepening acquisitions (Digital Additive in 2024 and Torrent Consulting in 2025) further strengthen CRM and multi‑cloud life‑sciences solutions.

Strategic Partnerships: An expanded Salesforce collaboration around Agentforce and recognition as Databricks 2025 Life Sciences Partner of the Year suggest momentum in data/AI ecosystems. These alliances position the firm to capture spend where CRM, data, and AI converge in healthcare and life sciences.

Strong Revenue Growth: Total revenue increased to $255.9M in 2025 with software up and drug‑discovery more than doubling, while operating expenses declined year over year. Early 2026 also showed momentum, with first‑half revenue modestly higher and Q2 posting year‑over‑year growth.

Strategic Partnerships: New and expanded agreements—such as Bristol Myers Squibb deploying Bunsen and a July 2026 discovery collaboration with Simcere—broaden platform use and collaboration optionality. The Lilly/Ajax transaction also validated the model and supported a higher 2026 drug‑discovery outlook.

Product Line Growth: The introduction of Bunsen, an agentic AI co‑scientist, expands the software portfolio and is being deployed at scale within BMS. This product push complements growth in ACV and broader platform adoption.

Strong Market Position & Advantage: GSK is positioned as a top-tier global biopharmaceutical company by revenue while showing category leadership in vaccines and HIV, anchored by franchises such as Shingrix and ViiV’s portfolio. Its consistent top-10/12 standing and segment leadership in vaccines, respiratory, and HIV support a stable competitive footing.

Resilient & Sustainable Growth: Revenue and earnings momentum are supported by broad-based growth across Specialty Medicines and continued contributions from Vaccines, alongside reaffirmed multi-year sales ambitions. Guidance for continued turnover and profit expansion indicates an expectation of ongoing, steadier growth rather than a one-off spike.

Healthy Cash Flow: Operating cash generation is described as strong and is being used to fund R&D investment and shareholder returns such as dividends and buybacks. This cash profile supports resilience through investment cycles and potential volatility in specific product areas.

Strong Market Position & Advantage: Industry and company materials indicate ResMed is the leading player in global sleep‑apnea devices and masks, supported by scale and a large connected ecosystem (AirView/myAir). Philips’ U.S. consent decree and extended remediation have provided a multi‑year window that reinforced ResMed’s relative momentum.

Strong Revenue Growth: Recent quarters show continued year‑over‑year revenue growth with margin expansion, driven by device demand and recurring masks/accessories. Management commentary and investor materials point to sustained momentum through FY2026 to date.

Diversified Revenue Streams: A large installed base of connected devices underpins recurring resupply revenue and remote monitoring workflows. Ownership of Brightree and MatrixCare adds out‑of‑hospital software that complements the core hardware franchise.

Strong Market Position & Advantage: By market value and category leadership in incretins, Lilly sits at or near the top of global pharma. Mounjaro/Zepbound are redefining obesity/diabetes, with Mounjaro becoming the world’s best‑selling prescription drug in early 2026.

Strong Revenue Growth: Results show outsized, volume-led acceleration, with Q1 2026 revenue reaching $19.8B. Management also raised 2026 sales guidance to about $82–$85B after very strong 2025 growth.

Innovation-Driven Growth: Recent approvals and pipeline progress beyond metabolic disease add new growth pillars. The FDA approval of Kisunla (donanemab) in 2024 and advancement of oral GLP‑1 programs broaden the portfolio.

Strong Revenue Growth: Comparable revenue increased in FY2025 and the company reports a positive start to FY2026 on a comparable basis while reaffirming its full-year comparable growth guidance.

Profitability: Adjusted EBIT margin rose in FY2025, and free cash flow improved alongside a higher proposed dividend, indicating strengthened operating performance and shareholder returns.

Strong Market Position & Advantage: The company is positioned as a leader in medical technology, with noted dominance in diagnostic imaging and continued momentum in Imaging and Precision Therapy helping sustain growth despite pressures elsewhere.

Strong Market Position & Advantage: GE HealthCare is positioned as a top-tier global medical technology player with leadership across diagnostic imaging, ultrasound, and pharmaceutical diagnostics, supported by a very large installed base and operations in over 160 countries. Scale and portfolio breadth across major modalities and care settings are repeatedly presented as durable advantages that support recurring service, upgrades, and consumables/software revenue.

Innovation-Driven Growth: R&D investment exceeding $1B annually and an active pipeline of many products in imaging, digital health, and in vitro diagnostics indicate a sustained innovation engine. The emphasis on AI-enabled devices and new product introductions (e.g., photon-counting CT and other launches) is framed as a multi-year driver that should increase contribution to revenue over time.

Resilient & Sustainable Growth: Orders and backlog signals (book-to-bill above 1.0, growing orders, and a reported record backlog) suggest demand is keeping pace with shipments and provides forward visibility. Guidance for continued low-single-digit organic growth alongside expectations for EPS growth and meaningful free cash flow points to steady, defensible expansion rather than cyclical contraction.

Strong Revenue Growth: Recent quarters show accelerated top-line expansion with management increasing full-year growth guidance. Momentum reflects both organic gains and contributions from recent acquisitions.

Profitability: Operating metrics indicate healthy margins and rising earnings alongside revenue growth. Commentary highlights disciplined execution during peak demand periods while maintaining margin targets.

Innovation-Driven Growth: AI-led solutions, analytics, and automation are cited as material drivers of wins and efficiency across payer and provider workflows. New offerings and deployed AI use cases appear to be supporting scale and client expansion.

Strong Market Position & Advantage: HealthRules Payer is positioned as a leader in U.S. payer core administration, supported by repeated “Best in KLAS” mentions and ongoing Gartner recognition in core administrative processing. The company is also described as competing in a top tier with credible differentiation from a connected, modern payer platform.

Investor Backing & Capital Strength: A major ownership transition to Bain Capital and a reported multibillion-dollar transaction value indicate strong investor confidence and available capital for continued expansion. The combination with UST’s HealthProof is framed as a scale move intended to broaden the platform and accelerate growth.

Product Line Growth: The platform has expanded beyond core claims into payment integrity, care management, and member engagement through acquisitions such as The Burgess Group, Altruista Health, and Wellframe. Continued product scaling activity is highlighted through an AWS benchmark announcement intended to support very large plan volumes.

Strong Market Position & Advantage: The company is positioned as a top-tier global CRO with significant scale and a broad geographic footprint, supported by a major acquisition that strengthened its competitive standing. Operational activity indicators and industry recognition are presented as reinforcing its ability to win and execute large, complex trials.

Profitability: Earnings and operating profit metrics are described as improving in 2024, with increases in GAAP net income, adjusted earnings per share, and adjusted EBITDA. These results suggest the business maintained solid margin performance even as quarterly revenue fluctuated.

Resilient & Sustainable Growth: A large backlog and a book-to-bill above 1.0 in 2024 are cited as providing multi-year revenue visibility and demand coverage. Continued backlog levels into 2025 are described as a stabilizing factor despite a softer near-term revenue trajectory.

Strong Market Position & Advantage: Feedback suggests the company is viewed as top-tier in full-service clinical research delivery, supported by large global scale and repeated “Leader” placements in specific segments. The combination of clinical execution with data/analytics/technology is framed as a meaningful competitive advantage versus pure-play CROs.

Strong Revenue Growth: Feedback suggests recent results show continued revenue expansion, including a faster-growth latest quarter and full-year growth versus the prior year. Forward-looking demand indicators like bookings and contracted backlog are described as supporting continued activity.

Resilient & Sustainable Growth: Feedback suggests the business has multi-year revenue visibility through a large contracted backlog and book-to-bill above 1.0 in the CRO segment. Management guidance implies expectations of continued growth in the next year, reinforcing an outlook of durability.

Profitability: Adjusted EPS from continuing operations rose in the latest quarter and gross margin expanded year over year, with materials attributing gains to productivity and mix. Transformation initiatives are presented as supporting margin expansion and earnings growth even when reported sales are muted.

Healthy Cash Flow: Operating cash flow increased meaningfully year to date versus the prior period, and total debt declined, signaling strengthened liquidity. Cash generation is described as improving alongside margin gains.

Strong Market Position & Advantage: Brands such as Huggies and Kleenex hold leading share positions across many countries, and recent updates highlight holding or gaining share in a majority of tracked markets. This footprint and momentum indicate durable category advantage despite competitive intensity.